Company Profile

GeneRx+ Inc (AKA: GeneRx~TKTX Company~Transtk Inc)
Profile last edited on: 7/2/08      CAGE:       UEI:

Business Identifier: Developing and testing innovative gene therapies
Year Founded
1998
First Award
1997
Latest Award
2005
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3200 West End Avenue Suite 500
Nashville, TN 37203
   (615) 783-2165
   N/A
   www.generxplus.com
Location: Multiple
Congr. District: 05
County: Davidson

Public Profile

The original SBIR awards were made by NIH were to TransTk, a technology transfer company that helps researchers at university medical centers and at independent research institutions translate their scientific discoveries into potentially commercial products. These projects were then assigned to geneRx+ Inc. geneRx+ has identified a market for specially designed products that prevent and treat respiratory diseases that are not effectively treated by existing pharmaceuticals. geneRx+ is set up to develop products, carry out pre-clinical and clinical studies, and then license its products to fully-integrated pharmaceutical companies. The strategy is to create products based on innovative gene and protein-based technologies. These new products will have several advantages over conventional products such as a higher therapeutic efficacy and less frequent administration. geneRx+ has identified pulmonary conditions that currently lack effective treatments and may be treatable by these innovative therapies. geneRx+ plans to license its products to such companies that have the necessary resources to conduct Phase III trials and seek regulatory approval for marketing products to patients relatively early in development. The research willbe undertaken in geneRx+ laboratories and at in Georgia and at Emory University. Manufacturing will be done under contract with a GMP facility.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 2 NIH $856,143
Project Title: TGF-Beta for Pleurodesis
2005 1 NIH $97,589
Project Title: Development of Alpha-1 Antitrypsin Gene Therapeutic as Treatment for COPD
2003 2 NIH $885,508
Project Title: Improved Plasmid/Liposome Administration to the Lungs
2003 2 NIH $666,527
Project Title: P20, 'Molecular Shortstop' for Inflamatory Lung Diseases
2002 1 NIH $147,075
Project Title: Bionic Baroreflex System for Blood Pressure Control

Key People / Management

  Paul Ottaviano -- Director, President, and Chief Executive Officer

  Kenneth L Brigham

  Andre Diedrich

  Kirk B Lane

  Richard E Parker

  Jonathan R Sanders

  Robby Sanders -- Director of Research

  Arlene A Stecenko

Company News

There are no news available.